<DOC>
	<DOCNO>NCT00893464</DOCNO>
	<brief_summary>This study open-label , multicenter , phase 1 , dose-escalation study IXAZOMIB adult patient lymphoma . This study first administer IXAZOMIB patient lymphoma .</brief_summary>
	<brief_title>A Study IXAZOMIB Adult Patients With Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>1 . Male female patient 18 year old . 2 . Eastern Cooperative Oncology Group performance status 02 . 3 . Patients must confirm diagnosis lymphoma relapse and/or refractory least 2 prior chemotherapeutic regimen curative option exists . Patients Waldenstrom 's macroglobulinemia eligible enrollment study . Patients Hodgkin lymphoma consider eligible study . 4 . Suitable venous access PK pharmacodynamic evaluation . 5 . Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception abstain heterosexual intercourse . Male patient agree practice 2 effective method contraception abstain heterosexual intercourse . 6 . Voluntary write consent must obtain . 7 . Adequate blood chemistry value screen period : Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 ; platelet count ≥ 100,000/mm3 . Total bilirubin must ≤ 1.5 × upper limit normal range upper limit normal ( ULN ) . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) must ≤ 2.5 × upper limit normal ( ULN ) . AST ALT may elevate 5 time upper limit normal elevation reasonably ascribe presence metastatic disease . Calculated creatinine clearance ≥ 30 mL/minute . 1 . Peripheral neuropathy ≥ Grade 2 . 2 . Female patient lactate positive serum pregnancy test screening period . 3 . Major surgery within 14 day first dose treatment . 4 . Infection require systemic antibiotic therapy serious infection within 14 day first dose study treatment . 5 . Lifethreatening illness unrelated cancer . 6 . Diarrhea &gt; Grade 1 base NCI CTCAE categorization . 7 . Systemic antineoplastic therapy/or radiotherapy within 21 day first dose study treatment . 8 . Systemic treatment prohibit medication . 9 . Patient symptomatic brain metastasis . 10 . Evidence current uncontrolled cardiovascular condition , include cardiac arrhythmia , congestive heart failure ( CHF ) , angina , myocardial infarction within past 6 month . 11 . QTc &gt; 470 millisecond ( msec ) 12lead electrocardiogram ( ECG ) obtain screening period . 12 . Known human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C positive . 13 . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . 14 . Treatment investigational product within 28 day first dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>